Note: This data is extracted from a very large study from an International Workshop on treatment related leukemiasrestricted to balanced chromosome aberrations (i.e.: -5/del(5q) and -7/del(7q) not taken into account per see), published in Genes, Chromosomes and Cancer in 2002. 
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Clinics and pathology
Disease
Treatment related myelodysplasia (t-MDS) or acute non lymphocytic leukaemias (t-ANLL). Note The study included 41 cases; t-MDS with progression to ANLL accounted for 7% and t-ANLL for the remaining 93% the ANLL subtype was M3 in all but one case; no case of acute lymphoblastic leukaemia. Epidemiology t(15;17)(q22;q21) was found in 8% of t-MDS/t-ANLL; sex ratio: 15M/26F.
Clinics
Age at diagnosis of the primary disease 46 yrs (range 18-79); age at diagnosis of the t-MDS/t-ANLL: 49 yrs (range 19-81). Median interval was 29 mths (range: 9-175). Primary disease was a solid tumor in 71% of cases (breast cancer in particular) and a hematologic malignancy in 27%, treatment was radiotherapy (29%, a high proportion compared to other groups), chemotherapy (17%), or both (54%). Treatment included topoisomerase II inhibitors in 49% of cases and alkylating agents in 59%.
